Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol
Introduction Chronic Myeloid Leukaemia (CML) constitutes 15% of new adult leukaemia cases as well as 2%–3% of leukaemia in children under 15% and 9% of leukaemias in adolescents 15–19 years of age annually. The introduction of Tyrosine Kinase Inhibitors (TKI) therapy has dramatically improved surviv...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-09-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/9/9/e030092.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850221479121125376 |
|---|---|
| author | M Constantine Samaan Lehana Thabane Laura Banfield Janatani Balakumaran Tanisha Birk Breanne Golemiec Wryan Helmeczi Jeyanth Inkaran Yun-ya Kao Jennifer Leigh Sarah Saliba Rishi Sharma Laura Spatafora Kristin Wright William Yao Christopher Hillis Uma Athale |
| author_facet | M Constantine Samaan Lehana Thabane Laura Banfield Janatani Balakumaran Tanisha Birk Breanne Golemiec Wryan Helmeczi Jeyanth Inkaran Yun-ya Kao Jennifer Leigh Sarah Saliba Rishi Sharma Laura Spatafora Kristin Wright William Yao Christopher Hillis Uma Athale |
| author_sort | M Constantine Samaan |
| collection | DOAJ |
| description | Introduction Chronic Myeloid Leukaemia (CML) constitutes 15% of new adult leukaemia cases as well as 2%–3% of leukaemia in children under 15% and 9% of leukaemias in adolescents 15–19 years of age annually. The introduction of Tyrosine Kinase Inhibitors (TKI) therapy has dramatically improved survival in these patients, yet the off-target effects of this treatment may have long-term health impacts on CML survivors. The risk of adverse health outcomes is especially important in children, where TKI exposure may occur during critical windows of growth and puberty, and patients require treatment for prolonged periods of time. The aim of this systematic review protocol is to report on the methods used to conduct a systematic review to investigate the endometabolic and bone health effects of TKI therapy in CML.Methods and analysis Searches will be conducted in the Cochrane Central Register of Controlled Trials, EMBASE and MEDLINE from inception on August 1st, 2019. Searches may be updated while performing the systematic review to ensure new evidence is included if applicable. Grey literature search will include ClinicalTrials.gov and ProQuest Dissertations and Theses A&I. We will perform a meta-analysis if there are at least two studies reporting similar populations, interventions, methods and tracking the same outcome measures. The studies should also have similar age and sex distributions.Ethics and dissemination As this is a systematic review protocol, it does not include patient data; therefore, Research Ethics Board approval is not indicated. The systematic review will be published in a peer-reviewed journal and presented at international conferences.PROSPERO registration number CRD42018091175. |
| format | Article |
| id | doaj-art-4e39a760bbf6428bb8b40cebc7db4c07 |
| institution | OA Journals |
| issn | 2044-6055 |
| language | English |
| publishDate | 2019-09-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-4e39a760bbf6428bb8b40cebc7db4c072025-08-20T02:06:43ZengBMJ Publishing GroupBMJ Open2044-60552019-09-019910.1136/bmjopen-2019-030092Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocolM Constantine Samaan0Lehana Thabane1Laura Banfield2Janatani Balakumaran3Tanisha Birk4Breanne Golemiec5Wryan Helmeczi6Jeyanth Inkaran7Yun-ya Kao8Jennifer Leigh9Sarah Saliba10Rishi Sharma11Laura Spatafora12Kristin Wright13William Yao14Christopher Hillis15Uma Athale16Division of Pediatric Endocrinology, McMaster University, Hamilton, Ontario, CanadaDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, CanadaHealth Sciences Library, McMaster University, Hamilton, Ontario, CanadaDepartment of Pediatrics, McMaster University, Hamilton, Ontario, CanadaMichael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, CanadaMichael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, Canada3 Division of Internal Medicine, University of Ottawa, Ottawa, Ontario, CanadaMichael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, CanadaDepartment of Pediatrics, McMaster University, Hamilton, Ontario, CanadaMichael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, CanadaMichael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, CanadaSurgery, Hackensack Meridian Hackensack University Medical Center, Hackensack, New Jersey, USAMichael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, CanadaMichael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, CanadaMichael G. De Groote School of Medicine, McMaster University, Hamilton, Ontario, CanadaHamilton Health Sciences, Hamilton, Ontario, CanadaDepartment of Pediatrics, McMaster University, Hamilton, Ontario, CanadaIntroduction Chronic Myeloid Leukaemia (CML) constitutes 15% of new adult leukaemia cases as well as 2%–3% of leukaemia in children under 15% and 9% of leukaemias in adolescents 15–19 years of age annually. The introduction of Tyrosine Kinase Inhibitors (TKI) therapy has dramatically improved survival in these patients, yet the off-target effects of this treatment may have long-term health impacts on CML survivors. The risk of adverse health outcomes is especially important in children, where TKI exposure may occur during critical windows of growth and puberty, and patients require treatment for prolonged periods of time. The aim of this systematic review protocol is to report on the methods used to conduct a systematic review to investigate the endometabolic and bone health effects of TKI therapy in CML.Methods and analysis Searches will be conducted in the Cochrane Central Register of Controlled Trials, EMBASE and MEDLINE from inception on August 1st, 2019. Searches may be updated while performing the systematic review to ensure new evidence is included if applicable. Grey literature search will include ClinicalTrials.gov and ProQuest Dissertations and Theses A&I. We will perform a meta-analysis if there are at least two studies reporting similar populations, interventions, methods and tracking the same outcome measures. The studies should also have similar age and sex distributions.Ethics and dissemination As this is a systematic review protocol, it does not include patient data; therefore, Research Ethics Board approval is not indicated. The systematic review will be published in a peer-reviewed journal and presented at international conferences.PROSPERO registration number CRD42018091175.https://bmjopen.bmj.com/content/9/9/e030092.full |
| spellingShingle | M Constantine Samaan Lehana Thabane Laura Banfield Janatani Balakumaran Tanisha Birk Breanne Golemiec Wryan Helmeczi Jeyanth Inkaran Yun-ya Kao Jennifer Leigh Sarah Saliba Rishi Sharma Laura Spatafora Kristin Wright William Yao Christopher Hillis Uma Athale Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol BMJ Open |
| title | Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol |
| title_full | Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol |
| title_fullStr | Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol |
| title_full_unstemmed | Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol |
| title_short | Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol |
| title_sort | evaluating the endometabolic and bone health effects of tyrosine kinase inhibitors in chronic myeloid leukaemia a systematic review protocol |
| url | https://bmjopen.bmj.com/content/9/9/e030092.full |
| work_keys_str_mv | AT mconstantinesamaan evaluatingtheendometabolicandbonehealtheffectsoftyrosinekinaseinhibitorsinchronicmyeloidleukaemiaasystematicreviewprotocol AT lehanathabane evaluatingtheendometabolicandbonehealtheffectsoftyrosinekinaseinhibitorsinchronicmyeloidleukaemiaasystematicreviewprotocol AT laurabanfield evaluatingtheendometabolicandbonehealtheffectsoftyrosinekinaseinhibitorsinchronicmyeloidleukaemiaasystematicreviewprotocol AT janatanibalakumaran evaluatingtheendometabolicandbonehealtheffectsoftyrosinekinaseinhibitorsinchronicmyeloidleukaemiaasystematicreviewprotocol AT tanishabirk evaluatingtheendometabolicandbonehealtheffectsoftyrosinekinaseinhibitorsinchronicmyeloidleukaemiaasystematicreviewprotocol AT breannegolemiec evaluatingtheendometabolicandbonehealtheffectsoftyrosinekinaseinhibitorsinchronicmyeloidleukaemiaasystematicreviewprotocol AT wryanhelmeczi evaluatingtheendometabolicandbonehealtheffectsoftyrosinekinaseinhibitorsinchronicmyeloidleukaemiaasystematicreviewprotocol AT jeyanthinkaran evaluatingtheendometabolicandbonehealtheffectsoftyrosinekinaseinhibitorsinchronicmyeloidleukaemiaasystematicreviewprotocol AT yunyakao evaluatingtheendometabolicandbonehealtheffectsoftyrosinekinaseinhibitorsinchronicmyeloidleukaemiaasystematicreviewprotocol AT jenniferleigh evaluatingtheendometabolicandbonehealtheffectsoftyrosinekinaseinhibitorsinchronicmyeloidleukaemiaasystematicreviewprotocol AT sarahsaliba evaluatingtheendometabolicandbonehealtheffectsoftyrosinekinaseinhibitorsinchronicmyeloidleukaemiaasystematicreviewprotocol AT rishisharma evaluatingtheendometabolicandbonehealtheffectsoftyrosinekinaseinhibitorsinchronicmyeloidleukaemiaasystematicreviewprotocol AT lauraspatafora evaluatingtheendometabolicandbonehealtheffectsoftyrosinekinaseinhibitorsinchronicmyeloidleukaemiaasystematicreviewprotocol AT kristinwright evaluatingtheendometabolicandbonehealtheffectsoftyrosinekinaseinhibitorsinchronicmyeloidleukaemiaasystematicreviewprotocol AT williamyao evaluatingtheendometabolicandbonehealtheffectsoftyrosinekinaseinhibitorsinchronicmyeloidleukaemiaasystematicreviewprotocol AT christopherhillis evaluatingtheendometabolicandbonehealtheffectsoftyrosinekinaseinhibitorsinchronicmyeloidleukaemiaasystematicreviewprotocol AT umaathale evaluatingtheendometabolicandbonehealtheffectsoftyrosinekinaseinhibitorsinchronicmyeloidleukaemiaasystematicreviewprotocol |